Is creatine monohydrate safe for healthy adults, and what renal and hepatic monitoring is recommended?

Creatine Monohydrate Safety in Healthy Adults

Creatine monohydrate supplementation is safe for healthy adults at standard doses (3-5 g/day maintenance, 20 g/day loading for ≤5 days), with no evidence of renal or hepatic dysfunction requiring routine monitoring in individuals with normal baseline kidney function.

Safety Profile

The evidence consistently demonstrates that creatine supplementation does not impair kidney function in healthy individuals. Multiple studies show no adverse effects on glomerular filtration rate, albumin excretion, or other markers of renal function, even with prolonged use over several months 1, 2. A recent meta-analysis found only a small, transient increase in serum creatinine (0.07 µmol/L) without changes in GFR, indicating this reflects increased creatine metabolism rather than kidney damage 2.

Monitoring Recommendations

For healthy adults without pre-existing conditions: No routine renal or hepatic monitoring is required.

However, specific populations warrant caution and baseline assessment:

High-Risk Groups Requiring Pre-Supplementation Evaluation

• Pre-existing renal disease (any stage of CKD)
• Diabetes mellitus
• Hypertension
• Reduced baseline GFR (<60 mL/min/1.73m²)
• Pregnancy (insufficient safety data)
• Age <18 years (safety not established)

For these individuals, obtain baseline serum creatinine and eGFR before initiating supplementation 1, 3. The KDIGO guidelines emphasize that prescribers should account for GFR when considering any supplement that affects creatinine metabolism 4, 5.

Critical Caveats

Serum Creatinine as a False Marker

Creatine supplementation elevates serum creatinine through increased metabolic turnover, not kidney damage. In one controlled study, a patient with a solitary kidney showed increased serum creatinine (1.03→1.27 mg/dL) but unchanged measured GFR (81.6→82.0 mL/min/1.73m²) 6. This means creatinine-based eGFR becomes unreliable during creatine use—if precise GFR assessment is needed (e.g., drug dosing, pre-surgical evaluation), use cystatin C-based eGFR or direct GFR measurement 4, 5.

Contraindications

• Absolute: Significant renal impairment (eGFR <30 mL/min/1.73m²), pregnancy at term, active kidney disease
• Relative: Concurrent nephrotoxic medications (NSAIDs, lithium, calcineurin inhibitors), dehydration risk

Dosing Thresholds

Studies showing safety used:

• Loading: 20 g/day for 5 days maximum
• Maintenance: ≤5 g/day

Higher doses (>10 g/day long-term) lack adequate safety data 3. Benefits in older adults appear with ≥5 g/day combined with resistance training 7, 8.

Adverse Effects

Gastrointestinal distress (nausea, cramping) occurs in some individuals, particularly at loading doses, but is dose-dependent and not universal 9. One case report described acute tubular necrosis in an 18-year-old taking 20 g/day, though causality remains uncertain given the isolated nature of this report 10. Claims of dehydration, muscle cramps, and thermoregulatory dysfunction are not supported by controlled studies 9.

Practical Algorithm

For healthy adults (age ≥18, no kidney disease, normal BP, no diabetes):

1. Start 3-5 g/day maintenance dose (or 20 g/day × 5 days loading)
2. No routine monitoring required
3. Discontinue if GI symptoms develop

For individuals with risk factors:

1. Obtain baseline: serum creatinine, eGFR, urinalysis
2. If eGFR ≥60: May proceed with 3-5 g/day
3. If eGFR 30-59: Do not use 1
4. If eGFR <30: Contraindicated
5. Monitor creatinine/eGFR at 3 months if continuing

During acute illness (dehydration, infection): Temporarily discontinue, similar to guidance for other renally-handled substances 4, 5.

The theoretical concerns about carcinogenicity from heterocyclic amine formation lack experimental support, and regulatory warnings (e.g., French AFSSA) remain unsubstantiated 1.